Protalix BioTherapeutics, Inc. SEC filings PLX
Protalix BioTherapeutics, Inc. has 972 filings in SEC EDGAR's recent list, going back to Aug 13, 1996. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 25, 2026 |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 26, 2025 |
| DEFA14A | Additional proxy material | May 17, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 27, 2024 |
| DEFA14A | Additional proxy material | Jun 28, 2023 | — |
| DEF 14A | Proxy statement | May 18, 2023 | Jun 28, 2023 |
| PRE 14A | Preliminary proxy statement | May 2, 2023 | May 2, 2023 |
| DEFA14A | Additional proxy material | Jun 16, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 30, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2022 | Apr 14, 2022 |
| DEFA14A | Additional proxy material | Nov 9, 2021 | — |
| DEF 14A | Proxy statement | Sep 30, 2021 | Nov 24, 2021 |
| PRE 14A | Preliminary proxy statement | Sep 17, 2021 | Nov 24, 2021 |
| DEF 14A | Proxy statement | Jun 4, 2021 | Jul 7, 2021 |
| DEF 14A | Proxy statement | Apr 15, 2020 | Jun 7, 2020 |
| DEFA14A | Additional proxy material | Nov 26, 2019 | — |
| DEFA14A | Additional proxy material | Nov 15, 2019 | — |
| DEFA14A | Additional proxy material | Nov 12, 2019 | — |
| DEF 14A | Proxy statement | Oct 15, 2019 | Dec 9, 2019 |
| PRE 14A | Preliminary proxy statement | Oct 4, 2019 | Dec 9, 2019 |
| DEF 14A | Proxy statement | Apr 12, 2019 | May 30, 2019 |
| DEFA14A | Additional proxy material | Dec 19, 2018 | — |
| DEF 14A | Proxy statement | Oct 17, 2018 | Dec 13, 2018 |
| PRE 14A | Preliminary proxy statement | Oct 5, 2018 | Dec 13, 2018 |
| DEFA14A | Additional proxy material | Apr 18, 2018 | — |
| DEFA14A | Additional proxy material | Apr 2, 2018 | — |
| DEFA14A | Additional proxy material | Mar 23, 2018 | — |
| DEF 14A | Proxy statement | Mar 6, 2018 | Apr 15, 2018 |
| PRE 14A | Preliminary proxy statement | Feb 23, 2018 | Feb 23, 2018 |
| DEFA14A | Additional proxy material | Oct 10, 2017 | — |
| DEFA14A | Additional proxy material | Sep 18, 2017 | — |
| DEF 14A | Proxy statement | Sep 1, 2017 | Oct 19, 2017 |
| DEF 14A | Proxy statement | Aug 25, 2017 | Oct 19, 2017 |
| PRE 14A | Preliminary proxy statement | Aug 10, 2017 | Aug 10, 2017 |
| DEFA14A | Additional proxy material | Mar 29, 2017 | — |
| DEF 14A | Proxy statement | Mar 16, 2017 | Apr 12, 2017 |
| PRE 14A | Preliminary proxy statement | Mar 6, 2017 | Mar 6, 2017 |
| DEF 14A | Proxy statement | Jul 1, 2016 | Aug 7, 2016 |
| PRE 14A | Preliminary proxy statement | Jun 16, 2016 | Jun 16, 2016 |
| DEFA14A | Additional proxy material | Oct 26, 2015 | — |
| DEF 14A | Proxy statement | Oct 1, 2015 | Nov 8, 2015 |
| DEFA14A | Additional proxy material | Oct 29, 2014 | — |
| DEF 14A | Proxy statement | Oct 9, 2014 | Nov 10, 2014 |
| PRE 14A | Preliminary proxy statement | Sep 29, 2014 | Nov 10, 2014 |
| DEF 14A | Proxy statement | Sep 20, 2013 | Nov 7, 2013 |
| DEF 14A | Proxy statement | May 21, 2012 | Jun 17, 2012 |
| PRE 14A | Preliminary proxy statement | May 9, 2012 | Jun 17, 2012 |
| DEF 14A | Proxy statement | Sep 19, 2011 | Nov 7, 2011 |
| DEF 14A | Proxy statement | Oct 4, 2010 | Nov 7, 2010 |
| DEF 14A | Proxy statement | Sep 18, 2009 | Nov 9, 2009 |
| DEF 14A | Proxy statement | Oct 3, 2008 | Nov 9, 2008 |
| DEF 14A | Proxy statement | Dec 31, 2007 | Jan 31, 2008 |
| DEF 14C | Information statement | Jan 30, 2007 | Dec 14, 2006 |
| DEF 14C | Information statement | Jun 23, 2006 | Jun 30, 2006 |
| DEF 14A | Proxy statement | Apr 18, 1997 | May 23, 1997 |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PLX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hackensack, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1006281
- Former names
- ORTHODONTIX INC (until Feb 22, 2007); EMBASSY ACQUISITION CORP (until Mar 31, 1998)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.